_1777294237270_124456903.png&w=48&q=75){kind=small}
Spimaco and Genetix Partner for LYFGENIA and ZYNTEGLO
SeemaCo Saudi Arabia and its subsidiary SeemaCo Bio have signed an exclusive agreement with Genetix Biotherapeutics to develop, market, and manufacture the therapies LYFGENIA™ and ZYNTEGLO™ in Saudi Arabia and the Middle East region. The agreement aims to accelerate access to one-time gene therapies for patients with sickle cell disease and beta-thalassemia, leading to improved health outcomes and localizing biotech technologies, in line with Saudi Arabia’s Vision 2030 and the support of the regional biovaccine innovation ecosystem.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)